GSK, Valeant Willing To Exclude Some Epilepsy Patients From Potiga Market

GlaxoSmithKline and Valeant Pharmaceuticals appear willing to sacrifice a part of the target market for their anti-epileptic drug Potiga (ezogabine), as well as implement an extensive Risk Evaluation and Mitigation Strategy, in order to gain approval

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet